Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dietary Supplements | 4 | 2021 | 558 | 1.660 |
Why?
|
| Coronary Restenosis | 17 | 2009 | 63 | 1.610 |
Why?
|
| Ubiquinone | 2 | 2021 | 37 | 1.470 |
Why?
|
| Stents | 19 | 2010 | 1096 | 1.220 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 2195 | 0.940 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2021 | 849 | 0.840 |
Why?
|
| Angioplasty, Balloon, Coronary | 11 | 2009 | 314 | 0.730 |
Why?
|
| Muscle Weakness | 1 | 2021 | 116 | 0.730 |
Why?
|
| Ataxia | 1 | 2021 | 176 | 0.690 |
Why?
|
| Minerals | 1 | 2019 | 71 | 0.690 |
Why?
|
| Mitochondrial Diseases | 1 | 2021 | 137 | 0.680 |
Why?
|
| Preventive Health Services | 1 | 2019 | 75 | 0.660 |
Why?
|
| Vitamins | 1 | 2019 | 157 | 0.650 |
Why?
|
| Coronary Vessels | 10 | 2006 | 665 | 0.620 |
Why?
|
| Antioxidants | 1 | 2019 | 507 | 0.550 |
Why?
|
| Tunica Intima | 8 | 2005 | 117 | 0.470 |
Why?
|
| Brachytherapy | 7 | 2004 | 977 | 0.460 |
Why?
|
| Paclitaxel | 7 | 2009 | 1996 | 0.390 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 1303 | 0.370 |
Why?
|
| Magnetics | 2 | 2007 | 107 | 0.360 |
Why?
|
| Drug Delivery Systems | 5 | 2006 | 669 | 0.360 |
Why?
|
| Ultrasonography, Interventional | 7 | 2006 | 429 | 0.330 |
Why?
|
| Coronary Disease | 4 | 2007 | 764 | 0.310 |
Why?
|
| Sirolimus | 5 | 2012 | 814 | 0.300 |
Why?
|
| Coronary Angiography | 12 | 2009 | 598 | 0.280 |
Why?
|
| Heart Failure | 1 | 2019 | 2516 | 0.260 |
Why?
|
| Coronary Artery Disease | 4 | 2006 | 1011 | 0.240 |
Why?
|
| Cardiac Catheterization | 2 | 2007 | 687 | 0.230 |
Why?
|
| Angiogenesis Inhibitors | 3 | 2006 | 1248 | 0.220 |
Why?
|
| Coronary Stenosis | 3 | 2009 | 117 | 0.210 |
Why?
|
| Pulmonary Valve Stenosis | 1 | 2002 | 44 | 0.210 |
Why?
|
| Aneurysm | 1 | 2002 | 94 | 0.200 |
Why?
|
| Foramen Ovale, Patent | 2 | 2012 | 22 | 0.200 |
Why?
|
| Ischemic Attack, Transient | 2 | 2012 | 55 | 0.200 |
Why?
|
| Beta Particles | 4 | 2003 | 13 | 0.180 |
Why?
|
| Drug-Eluting Stents | 2 | 2012 | 131 | 0.180 |
Why?
|
| Prosthesis Design | 4 | 2009 | 749 | 0.170 |
Why?
|
| Catheterization | 1 | 2002 | 410 | 0.170 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 140 | 0.170 |
Why?
|
| Endosonography | 1 | 2002 | 536 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2002 | 499 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2019 | 2594 | 0.160 |
Why?
|
| Platelet Aggregation Inhibitors | 4 | 2012 | 444 | 0.160 |
Why?
|
| Syndrome | 1 | 2019 | 1351 | 0.140 |
Why?
|
| Hyperplasia | 6 | 2006 | 557 | 0.120 |
Why?
|
| Humans | 34 | 2021 | 261506 | 0.120 |
Why?
|
| Treatment Outcome | 11 | 2019 | 32848 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 1085 | 0.120 |
Why?
|
| Energy Metabolism | 1 | 2019 | 992 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2019 | 1129 | 0.110 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.110 |
Why?
|
| Durapatite | 1 | 2012 | 31 | 0.110 |
Why?
|
| Stroke | 2 | 2012 | 1144 | 0.110 |
Why?
|
| Embolism, Paradoxical | 1 | 2012 | 6 | 0.110 |
Why?
|
| Graft Occlusion, Vascular | 2 | 2003 | 118 | 0.110 |
Why?
|
| Materials Testing | 1 | 2012 | 116 | 0.110 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2012 | 68 | 0.110 |
Why?
|
| Platelet Activation | 1 | 2012 | 116 | 0.100 |
Why?
|
| Intracranial Embolism | 1 | 2010 | 39 | 0.100 |
Why?
|
| Cardiovascular Agents | 1 | 2009 | 128 | 0.080 |
Why?
|
| Angina, Unstable | 1 | 2007 | 70 | 0.070 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2010 | 303 | 0.070 |
Why?
|
| Dilatation | 1 | 2006 | 83 | 0.070 |
Why?
|
| Acute Coronary Syndrome | 1 | 2009 | 259 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2012 | 1375 | 0.070 |
Why?
|
| Polymers | 2 | 2005 | 223 | 0.070 |
Why?
|
| Retreatment | 2 | 2007 | 452 | 0.070 |
Why?
|
| Metals | 1 | 2006 | 155 | 0.070 |
Why?
|
| Platelet Adhesiveness | 1 | 2005 | 57 | 0.060 |
Why?
|
| Apyrase | 1 | 2005 | 44 | 0.060 |
Why?
|
| Carotid Stenosis | 1 | 2006 | 176 | 0.060 |
Why?
|
| Recurrence | 2 | 2004 | 4758 | 0.060 |
Why?
|
| Iliac Artery | 1 | 2005 | 108 | 0.060 |
Why?
|
| Angiopoietin-2 | 1 | 2005 | 38 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2006 | 286 | 0.060 |
Why?
|
| Radiography, Interventional | 1 | 2007 | 305 | 0.060 |
Why?
|
| Hindlimb | 1 | 2005 | 105 | 0.060 |
Why?
|
| Stainless Steel | 1 | 2004 | 26 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 185 | 0.060 |
Why?
|
| Mitomycin | 1 | 2005 | 208 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 324 | 0.060 |
Why?
|
| Platelet Aggregation | 1 | 2005 | 257 | 0.060 |
Why?
|
| Angioplasty, Balloon | 1 | 2005 | 183 | 0.060 |
Why?
|
| Pericarditis, Constrictive | 1 | 2003 | 11 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2005 | 4938 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 528 | 0.060 |
Why?
|
| Mitral Valve Stenosis | 1 | 2003 | 50 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2007 | 1391 | 0.060 |
Why?
|
| HIV | 1 | 2005 | 229 | 0.060 |
Why?
|
| Ticlopidine | 3 | 2012 | 95 | 0.060 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 592 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2005 | 305 | 0.060 |
Why?
|
| Aortic Diseases | 1 | 2005 | 206 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 345 | 0.050 |
Why?
|
| Thrombosis | 2 | 2009 | 781 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2002 | 88 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2007 | 925 | 0.050 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.050 |
Why?
|
| Ischemia | 1 | 2005 | 391 | 0.050 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 214 | 0.050 |
Why?
|
| Gamma Rays | 1 | 2002 | 242 | 0.050 |
Why?
|
| Hemangiosarcoma | 1 | 2003 | 234 | 0.050 |
Why?
|
| Animals | 7 | 2019 | 59536 | 0.050 |
Why?
|
| Aspirin | 3 | 2012 | 455 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2005 | 1385 | 0.040 |
Why?
|
| Male | 16 | 2012 | 123000 | 0.040 |
Why?
|
| Secondary Prevention | 2 | 2012 | 329 | 0.040 |
Why?
|
| Phosphorus Radioisotopes | 3 | 2003 | 44 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 1533 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2002 | 945 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2002 | 2307 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 891 | 0.040 |
Why?
|
| Genetic Therapy | 1 | 2005 | 1616 | 0.040 |
Why?
|
| Middle Aged | 14 | 2012 | 86204 | 0.040 |
Why?
|
| Female | 16 | 2012 | 141928 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2009 | 4320 | 0.040 |
Why?
|
| Endpoint Determination | 2 | 2010 | 176 | 0.030 |
Why?
|
| Prospective Studies | 5 | 2010 | 12873 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2002 | 705 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2002 | 1824 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2010 | 14889 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2007 | 2588 | 0.030 |
Why?
|
| Time Factors | 4 | 2012 | 12926 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2002 | 3842 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 2315 | 0.030 |
Why?
|
| Linear Models | 2 | 2006 | 1085 | 0.030 |
Why?
|
| Swine | 2 | 2006 | 1541 | 0.030 |
Why?
|
| Warfarin | 1 | 2012 | 152 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2012 | 295 | 0.020 |
Why?
|
| Migraine Disorders | 1 | 2010 | 79 | 0.020 |
Why?
|
| Logistic Models | 2 | 2009 | 3441 | 0.020 |
Why?
|
| Blood Coagulation Disorders | 1 | 2010 | 120 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2010 | 203 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2006 | 4971 | 0.020 |
Why?
|
| Histological Techniques | 1 | 2006 | 65 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2012 | 787 | 0.020 |
Why?
|
| Cholesterol Esters | 1 | 2005 | 34 | 0.020 |
Why?
|
| Adult | 3 | 2012 | 77950 | 0.020 |
Why?
|
| Injections, Intra-Arterial | 1 | 2005 | 62 | 0.020 |
Why?
|
| Receptors, Thrombin | 1 | 2005 | 23 | 0.020 |
Why?
|
| Safety | 1 | 2007 | 465 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 2005 | 87 | 0.020 |
Why?
|
| Adenosine Diphosphate | 1 | 2005 | 113 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 671 | 0.020 |
Why?
|
| Solubility | 1 | 2005 | 242 | 0.020 |
Why?
|
| Half-Life | 1 | 2005 | 259 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 7548 | 0.020 |
Why?
|
| Sus scrofa | 1 | 2005 | 169 | 0.020 |
Why?
|
| Liposomes | 1 | 2006 | 684 | 0.020 |
Why?
|
| Diabetic Angiopathies | 1 | 2005 | 78 | 0.020 |
Why?
|
| Systole | 1 | 2005 | 196 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2005 | 134 | 0.020 |
Why?
|
| Coronary Thrombosis | 1 | 2004 | 44 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 235 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2005 | 330 | 0.010 |
Why?
|
| Viral Envelope Proteins | 1 | 2005 | 207 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.010 |
Why?
|
| Rabbits | 1 | 2005 | 957 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2005 | 503 | 0.010 |
Why?
|
| Aged | 5 | 2009 | 70117 | 0.010 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 2006 | 7222 | 0.010 |
Why?
|
| Equipment Failure | 1 | 2003 | 191 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2003 | 409 | 0.010 |
Why?
|
| Models, Animal | 1 | 2005 | 664 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2005 | 14289 | 0.010 |
Why?
|
| Europe | 1 | 2004 | 649 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6207 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 752 | 0.010 |
Why?
|
| Registries | 1 | 2009 | 2170 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2003 | 829 | 0.010 |
Why?
|
| Cell Division | 1 | 2005 | 2489 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2005 | 1363 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2005 | 2063 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 4988 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2005 | 546 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 8865 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2009 | 1374 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 1073 | 0.010 |
Why?
|
| Equipment Design | 1 | 2003 | 1204 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2005 | 1694 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 4917 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2003 | 2292 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 6089 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2005 | 5637 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2002 | 674 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 6869 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2002 | 2231 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2012 | 5542 | 0.010 |
Why?
|
| Rats | 1 | 2005 | 6086 | 0.010 |
Why?
|
| Hypertension | 1 | 2006 | 1503 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 1054 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2002 | 1145 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 6150 | 0.010 |
Why?
|
| Texas | 1 | 2006 | 6311 | 0.010 |
Why?
|
| Survival Rate | 1 | 2007 | 12221 | 0.010 |
Why?
|
| Young Adult | 1 | 2012 | 21445 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 5673 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 6682 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 3719 | 0.010 |
Why?
|
| United States | 1 | 2009 | 15433 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2007 | 37905 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 31252 | 0.010 |
Why?
|